CytomX Therapeutics (CTMX) Announces Earnings Results

CytomX Therapeutics (NASDAQ:CTMX) released its earnings results on Tuesday. The biotechnology company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.11), Fidelity Earnings reports. CytomX Therapeutics had a negative return on equity of 74.84% and a negative net margin of 44.46%. The business had revenue of $12.51 million for the quarter, compared to analyst estimates of $16.42 million.

Shares of CTMX stock traded up $3.20 on Wednesday, hitting $15.95. The stock had a trading volume of 1,315,395 shares, compared to its average volume of 402,168. CytomX Therapeutics has a twelve month low of $12.75 and a twelve month high of $35.00. The firm has a market capitalization of $674.91 million, a price-to-earnings ratio of -13.75 and a beta of 1.46.

Several equities analysts have recently issued reports on the stock. BidaskClub lowered shares of CytomX Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, September 11th. HC Wainwright assumed coverage on shares of CytomX Therapeutics in a report on Thursday, September 13th. They issued a “buy” rating and a $32.00 price target for the company. Goldman Sachs Group assumed coverage on shares of CytomX Therapeutics in a report on Monday, October 15th. They issued a “neutral” rating and a $21.00 price target for the company. Cann reissued a “hold” rating on shares of CytomX Therapeutics in a report on Tuesday. Finally, Zacks Investment Research lowered shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 13th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $34.88.

In related news, insider Sean A. Mccarthy sold 6,526 shares of the business’s stock in a transaction on Friday, November 2nd. The shares were sold at an average price of $15.00, for a total value of $97,890.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Debanjan Ray sold 3,000 shares of the business’s stock in a transaction on Tuesday, September 4th. The shares were sold at an average price of $22.39, for a total transaction of $67,170.00. Following the completion of the sale, the chief financial officer now directly owns 8,928 shares in the company, valued at $199,897.92. The disclosure for this sale can be found here. Insiders sold a total of 28,578 shares of company stock valued at $550,757 in the last three months. 8.50% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of CTMX. Great West Life Assurance Co. Can lifted its position in CytomX Therapeutics by 174.6% in the 2nd quarter. Great West Life Assurance Co. Can now owns 4,943 shares of the biotechnology company’s stock valued at $113,000 after acquiring an additional 3,143 shares in the last quarter. SG Americas Securities LLC bought a new stake in CytomX Therapeutics in the 2nd quarter valued at $119,000. WINTON GROUP Ltd bought a new stake in CytomX Therapeutics in the 1st quarter valued at $205,000. Xact Kapitalforvaltning AB bought a new stake in CytomX Therapeutics in the 2nd quarter valued at $206,000. Finally, Fox Run Management L.L.C. bought a new stake in CytomX Therapeutics in the 3rd quarter valued at $225,000. 71.53% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “CytomX Therapeutics (CTMX) Announces Earnings Results” was first published by WKRB News and is owned by of WKRB News. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://www.wkrb13.com/2018/11/07/cytomx-therapeutics-ctmx-announces-earnings-results.html.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

See Also: Put Option

Earnings History for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply